Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data

Nakahama, Kenji; Izumi, Motohiro; Yoshimoto, Noriko; Fukui, M; Sugimoto, Akira; Nagamine, Hiroaki; Ogawa, Kōichi; Sawa, Kenji; Tani, Yoko; Mitsuoka, Shigeki; Watanabe, Tetsuya; Asai, Kuniya; Kawaguchi, Tomoya

doi:10.21873/anticanres.16381

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we found that smoking is an actionable biomarker for predicting MPR with NACI. Similar results have been reported in advanced NSCLC 43 – 47 . Moreover, in one study, smoking signature performed better than PD-L1 expression in predicting the pathological response in a neoadjuvant cohort, which might be explained by increased TMB and/or MSI resulted from tobacco exposure 48 .…”

Section: Discussionsupporting

confidence: 90%

Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

Hu,

Li,

Lin

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

Background: Neoadjuvant chemoimmunotherapy (NACI) is promising for resectable non-small cell lung cancer (NSCLC), but predictive biomarkers are still lacking. We aimed to develop a model based on pretreatment parameters to predict major pathological response (MPR) for such an approach. Methods: We enrolled operable NSCLC treated with NACI between March 2020 and May 2023 and then collected baseline clinical-pathology data and routine laboratory examinations before treatment. The efficacy and safety data of this cohort was reported and variables were screened by Logistic and Lasso regression and nomogram was developed. In addition, receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were used to assess its power. Finally, internal cross-validation and external validation was performed to assess the power of the model. Results: In total, 206 eligible patients were recruited in this study and 53.4% (110/206) patients achieved MPR. Using multivariate analysis, the predictive model was constructed by seven variables, prothrombin time (PT), neutrophil percentage (NEUT%), large platelet ratio (P-LCR), eosinophil percentage (EOS%), smoking, pathological type, and programmed death ligand-1 (PD-L1) expression finally. The model had good discrimination, with area under the ROC curve (AUC) of 0.775, 0.746 and 0.835 for all datasets, cross-validation and external validation, respectively. The calibration curves showed good consistency, and DCAs indicated its potential value in clinical practice. Conclusion: This real world study revealed favourable efficacy in operable NSCLC treated with NACI. The proposed model based on multiple clinically accessible parameters could effectively predict MPR probability and could be a powerful tool in personalized medication.

show abstract

Section: Discussionsupporting

confidence: 90%

Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

Hu,

Li,

Lin

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Advancements in biomarker-driven targeted therapies are swiftly transforming the landscape of lung cancer treatment (4). From an epidemiological standpoint, the most prominent factor implicated in lung carcinogenesis is the enduring individual habit of tobacco consumption, which also proves valuable in predicting lung cancer prognosis (5,6). Cigarettes contain a diverse array of carcinogens that elevate reactive oxygen species, leading to DNA adducts and strand breaks in lung tissues and cells.…”

mentioning

confidence: 99%

The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan

CHIU,

WANG,

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Numerous studies have reported the over-expression of the radiation-sensitive protein 51 (RAD51) in various types of cancer. However, the role of RAD51 genotypes in lung cancer remains largely unknown. This study aimed to assess the impact of the common variant RAD51 rs1801320 (G-135C) genotypes on the risk of lung cancer in Taiwan. Materials and Methods: The contribution of RAD51 rs1801320 genotypes to lung cancer risk was investigated in a cohort comprising 358 lung cancer patients and 716 age-and sex-matched healthy controls, utilizing polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Results: The analysis revealed that among the control subjects, the percentages of GG, CG, and CC genotypes of RAD51 rs1801320 were 73.2%, 24.3%, and 2.5%, respectively. Among the lung cancer patients, these percentages were 71.0%, 25.1%, and 3.9%, respectively (p for trend=0.4075). Allelic frequency distributions showed no significant association between the C allele of RAD51 rs1801320 and lung cancer risk determination (p=0.2987). Specifically, the RAD51 rs1801320 CC genotypes were associated with an elevated risk of lung cancer among males [adjusted odds ratio (aOR)=2.28, 95% confidence interval (95%CI)=1. , but not among females and non-smokers. Conclusion: The RAD51 rs1801320 CC genotype was identified as a risk factor for elevated lung cancer risk in males and smokers. This genotype may serve as a molecular biomarker at the DNA level for early detection and prediction of lung cancer in Taiwan.

show abstract

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

Lee,

Menis,

Kim

et al. 2024

ESMO Open

View full text Add to dashboard Cite

Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data

Cited by 4 publications

References 0 publications

Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

Contact Info

Product

Resources

About